Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02367807 · ClinicalTrials.gov registry record
PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color
A clinical trial of HIV, sponsored by Philadelphia Fight.
- Completed
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT02367807: Completed study of HIV, sponsored by Philadelphia Fight.
NCT02367807 is a study of HIV that has completed, run by Philadelphia Fight. The registered enrollment target is 50 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02367807, a study of HIV, has completed, sponsored by Philadelphia Fight.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 48-week prospective observational study that will allow testing of the hypothesis that a program in which pre-exposure prophylaxis (PrEP) is administered to young men of color who have sex with men (yMSMc) in a community youth drop-in center in conjunction with a multifaceted behavioral intervention as well as standard HIV prevention interventions can achieve at least 70% retention, as well as a medication adherence rate significantly better than that previously reported in the literature. The proposed program evaluation can provide critical information for the enhancement and scale-up of successful PrEP programs at FIGHT and elsewhere in an effort to make PrEP available to a growing number of persons at risk of acquiring human immunodeficiency virus (HIV).
Primary Outcome
We will determine whether this community intervention can achieve 70% program retention at the end of 48 weeks, as defined by the proportion of patients initiating Truvada who pick up at least 50% of their medication through 48 weeks and who have a study visit in the 48-week window (subject may have this final study visit within an allowed window of 4 weeks before or after the 48-week visit in accordance with the FDA snapshot algorithm). Intermediate retention assessment will also be conducted a
Conditions Studied
Interventions
- DRUG Emtricitabine and tenofovir disoproxil fumarate
Study Locations (1)
Pennsylvania
- Philadelphia FIGHT - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-08 |
What the finished NCT02367807 record still lists
NCT02367807 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (89% lower).
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Emtricitabine and tenofovir disoproxil fumarate is the first listed.
NCT02367807 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02367807 about?
NCT02367807 is a clinical study titled "PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color". This is a 48-week prospective observational study that will allow testing of the hypothesis that a program in which pre-exposure prophylaxis (PrEP) is administered to young men of color who have sex with men (yMSMc) in a community youth drop-in center in conjunction with a multifaceted behavioral in...
What is the current status of trial NCT02367807?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2015-02. Estimated completion is 2016-08.
What conditions does trial NCT02367807 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT02367807?
The interventions under investigation include: Emtricitabine and tenofovir disoproxil fumarate (DRUG).
Who is sponsoring clinical trial NCT02367807?
This trial is sponsored by Philadelphia Fight, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02367807 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02367807's enrollment target sits among peer trials
50 219th of 303 higher than 73 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transitional Housing and HIV Health
RECRUITING
-
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
RECRUITING · Phase 1
-
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
RECRUITING
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
- NCT01746836 · 50 participants · Phase 2
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia